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S U M M A R Y
Early detection and effective treatment are crucial for tuberculosis control, but global case detection
rates remain low. The diagnosis of paediatric and extrapulmonary disease is problematic and there are,
as yet, no rapid screening tests to assist active case ﬁnding in the community. Progress has been made in
clinic-based detection tools with the introduction of Xpert MTB/RIF, a nucleic acid ampliﬁcation test that
combines sample processing and analysis in a single instrument to provide a diagnostic result and
detection of resistance to rifampicin in under 2 h. Enthusiasm for Xpert MTB/RIF has been high and
global rollout has been facilitated by donor agencies. However, concerns remain about access and
sustainability due to the high cost and infrastructure requirements. Although more sensitive than smear
microscopy, early studies suggest the impact of the new test on case detection rates and patient survival
has been limited. Alternative technologies are being developed, including non-sputum-based tests to
assist the detection of extrapulmonary disease. Evaluation studies are needed to provide evidence of the
impact of the new technologies on patient outcomes. This will enable appropriate placement of new
diagnostic products in the healthcare system to support the control and eventual eradication of
tuberculosis disease.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The old adage of ‘prevention being better than cure’, ﬁrst
enunciated by Hippocrates two and a half thousand years ago,
endures to this day as tuberculosis (TB) control programs
worldwide strive to prevent onward transmission of the disease.
Fundamental to their success is early case detection and access to
effective treatment.1 World Health Organization (WHO) data
suggest that global case detection rates are disappointing, with an
estimated three million cases failing to be notiﬁed each year.2,3 As
shown in Figure 1, during 2013 the WHO Africa region experienced
the lowest case detection rate, estimated at just 52% of new cases,
while in Southeast Asia an estimated 1.3 million TB cases failed to
be notiﬁed.
Until recently, knowledge of infection with Mycobacterium
tuberculosis was sufﬁcient to administer cure, but the emergence of
strains resistant to anti-TB drugs means that for some patients* Corresponding author. Tel.: +44 (0)7557020305.
E-mail address: Ruth.Mcnerney@gmail.com (R. McNerney).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).additional information is needed to access effective therapy.4,5 TB
case detection is beset by numerous problems. The slow onset and
lack of speciﬁc symptoms makes the disease difﬁcult to recognize
in the early stages and patients may delay for weeks or months
before seeking medical assistance, during which time they may
transmit the disease to others.6,7 When patients seek care at their
local health centre, access to treatment may be delayed due to the
lack of effective diagnostic tools, with detection of early-stage
disease, extrapulmonary, HIV co-infected, and paediatric cases
being particularly problematic. Screening tools based on clinical
assessment and patient history have been developed, but may be of
more value in monitoring treatment than for early diagnosis.8–10
There are two opportunities where intervention with improved
diagnostic tools might aid case detection and reduce transmission:
ﬁrstly in screening to detect new cases in the community in order
to avoid delay in health-seeking behaviour, and secondly to
improve the investigation of symptomatic patients presenting at
the clinic. Technical speciﬁcations for the two scenarios differ
considerably. A screening test should have high sensitivity, but
speciﬁcity is less critical if conﬁrmatory tests will be performed.
Screening tests must be inexpensive, easy to use, and rapid, withciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Figure 1. Tuberculosis case detection in 2013. Estimated number of incident TB
cases and number of notiﬁed cases by World Health Organization (WHO) region
during 2013. Compiled with data from the WHO TB Control Report 2014.3
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algorithm used at the point of care should be highly speciﬁc to
avoid false-positive diagnoses and inappropriate treatment.
2. Testing at the point of care
Treatment for TB entails a program of multi-drug therapy for a
period of at least 6 months, preferably with direct observation for
the ﬁrst 2 months. Patients need instruction, advice, and
counselling, and the point at which TB treatment is initiated is
usually a clinic, health centre, or hospital. Diagnosis in such
settings is based on clinical examination, patient history, and a
range of diagnostic tools, dependant on their availability. For
patients attending clinics in TB endemic countries, the choice of
diagnostic tests is often limited to smear microscopy, a low cost
technology of limited diagnostic utility due to the paucity of
bacteria in clinical specimens.2,11
The emergence of nucleic acid ampliﬁcation tests (NAATs) as a
diagnostic tool in the 1990s resulted in a new generation of
diagnostic tests. However, TB proved a challenging disease, as
extensive chemical and physical treatment was required to extract
the bacteria, release the DNA, remove inhibitors, and concentrate
the samples.12 NAATs were found to be less sensitive than culture
for diagnosing TB, but were highly speciﬁc and had the ability to
detect new TB cases in hours.13,14 NAATs are used widely in Europe
and two tests received approval from the United States Food and
Drug Administration (US FDA) to assist the diagnosis of TB: the
AMPLICOR M. tuberculosis test (Roche Diagnostic Systems, USA),
and the Ampliﬁed Mycobacterium Tuberculosis Direct test (MTD)
(Gen-Probe, Inc., USA).15 The commercial tests performed well
during research projects in Africa,16,17 but the high cost and level of
technical support needed prevented widespread adoption in TB
endemic countries.
2.1. Second-generation nucleic acid detection
Recognition that the failure to detect TB on a global scale is
preventing effective control of the disease encouraged investment
from public and philanthropic sources for the adaptation oftechnology initially developed for homeland security and the
detection of anthrax in the USA.18 The GeneXpert analyser
(Cepheid, USA) is a NAAT platform that integrates sample
preparation, ampliﬁcation, and detection of DNA, removing the
need for laboratory facilities or specialist technical skills. The Xpert
MTB/RIF assay detects M. tuberculosis DNA in under 2 h and detects
mutations that cause resistance to the key drug rifampicin. Initial
studies by the test developers suggested high sensitivity and
speciﬁcity for detecting both disease and drug resistance,19,20 but
subsequent concerns regarding false-positive resistance results
have led to recommendations in some jurisdictions that samples
found resistant be conﬁrmed by a second Xpert MTB/RIF test or, as
in the case of South Africa, a line probe assay (LiPA) and phenotypic
testing.21–23
As with previous NAAT technologies, the Xpert MTB/RIF test is
less sensitive than culture but more sensitive than microscopy, and
the ability to safely detect TB and resistance to rifampicin without
referral to a specialist laboratory has been hailed as a game-
changer in TB diagnostics.18 The test has been approved by the US
FDA for patients who have received less than 3 days of treatment,
with the recommendation that culture also be performed.24 The
WHO endorsed the technology in 2010 and it has been promoted
heavily in TB endemic countries for use at, or near the point at
which care is provided.25 Numerous studies have now been
published demonstrating the test to be more sensitive than smear
microscopy, and recommendations have been issued for its use to
investigate paediatric and extrapulmonary cases. However, some
frustrations have been expressed about the inability to monitor
treatment due to the persistence of bacterial DNA in patient
sputum,26,27 a problem common to all NAAT tests.28
Studies on the impact of the new technology have been less
conclusive and expectations that the implementation of Xpert
MTB/RIF would lead to dramatic increases in case detection with
improved cure rates have yet to be borne out. A multi-country
study in Sub-Saharan Africa found that although the new test
facilitated access to same-day initiation of treatment, the beneﬁts
did not translate into lower TB-related morbidity.29 Similarly, a
randomized controlled trial in Zimbabwe found screening with
Xpert MTB/RIF did not reduce the rate of antiretroviral therapy-
associated TB and mortality, as compared with ﬂuorescence
microscopy.30 This is in part due to the practice of prescribing anti-
TB therapy on clinical presentation and history, despite samples
being negative in tests for the bacteria. In such cases the NAAT
result has no bearing on treatment outcome.31 Impact is also
limited by the positioning of the technology within clinics as it
does not address patient delay in seeking a diagnosis. Studies to
assess the impact of rapid detection of drug resistance are ongoing,
as in settings where second-line therapies are available, the rapid
detection of resistance may prove beneﬁcial for patient outcomes
and lowered transmission. When used in a routine operational
setting in Cape Town, South Africa, it decreased the time to
commencement of second-line treatment by 25 days to a median
time of 17 days.32 However, should clinicians be reluctant to use
the test when no, or only substandard, multidrug-resistant (MDR)
TB treatment is available, then incorporation of a drug resistance
test may constitute a barrier to implementation.
In addition to assessing clinical performance, rollout has
exposed limitations of the technology and has provided increased
understanding of how the test should be applied.26 The test
requires a trained and computer-literate operator, a stable supply
of electricity, and in some settings air conditioning to moderate
operating and storage temperatures. Throughput is moderate to
low, depending on the model of instrument purchased. Concerns
have been expressed about sustainability of the technology due to
the high cost of manufacture. Agreement has been reached
between the manufacturers of the test, Cepheid Inc., and a
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Foundation, the United States Agency for International Develop-
ment, and the United States President’s Emergency Plan for AIDS
Relief) to reduce the cost of a reaction cartridge to USD 9.98 for
low-income countries, and UNITAID has invested USD 25.9 million
to supply instruments and cartridges for 21 high-burden countries
in Africa, Asia, and Eastern Europe. Rollout through donor funding
resulted in considerable challenges for distribution and supply
when large orders were placed in line with donor funding cycles,
without due consideration of training requirements, installation,
and start up times or the shelf-life of the reagents. Following stock-
outs and a period during 2012 when the company could not satisfy
demand, concerns have been expressed about reliance on a single
supplier.26
2.2. Next-generation nucleic acid ampliﬁcation
The next generation of TB NAAT products aim to acquire market
share by virtue of their reduced cost, decreased time to result, and
improved robustness and portability. A summary of NAAT
technologies in development is presented in Table 1.
Miniaturization is being exploited as a means of minimizing
reagent costs and increasing the speed of the ampliﬁcation
reaction. Isothermal ampliﬁcation methods have been developed,
where the thermocycling steps required for PCR are replaced by a
single constant temperature step, which shortens the assay time and
reduces the complexity of the device. Typically reaction tempera-
tures are 62–65 8C. Efforts to reduce dependency on an electrical
supply have resulted in accessory products that exploit exothermic
chemical reactions to provide elevated temperatures.33 An alterna-
tive development is recombinase polymerase ampliﬁcation, an
enzyme-dependant reaction that functions at temperatures be-
tween 25 and 42 8C. The detection of M. tuberculosis in processed
sputum was achieved with high speciﬁcity in less than 20 min at
39 8C, with reported sensitivities of 91.4% (95% conﬁdence interval
(CI) 85–97.9%) and 87.5% (95% CI 81.7–93.2%), dependant on the
DNA insertion element targeted.34Table 1
Nucleic acid ampliﬁcation technologies intended for use at the point of care for the di
Technology Ampliﬁcation
reaction
Operational features T
EasyNAT Cross priming
ampliﬁcation
Isothermal 65 8C
Instrument free visual output
Instrument free DNA extraction
I
Xpert TB/RIF PCR Automated sample extraction
Resistance to rifampicin
r
NEAT Nicking enzyme
ampliﬁcation reaction
Isothermal 55 8C to 59 8C 
RPA Recombinase
polymerase
ampliﬁcation
Isothermal 39 8C I
I
Truenat PCR Miniaturized chip-based
Semi-automated DNA extraction
R
d
r
VerePLEX Lab-
On-Chip
PCR Microarray technology
Rifampicin and isoniazid
resistance plus nine
non-TB mycobacteria
I
1
Genedrive PCR Paper-based DNA
extraction technology
Rifampicin resistance
R
r
PCR, polymerase chain reaction; CE mark, conformity mark for products sold within the
Health Organization; TB, tuberculosis.
a Includes sample extraction.However, whilst advances have been made in nucleic acid
ampliﬁcation technology, sample handling and extraction of the
DNA remain stumbling blocks. Attempts to replace the sophisti-
cated and expensive technology used by the Xpert MTB/RIF with
cheaper alternatives have yet to be proven in independent
evaluation studies. To date three new rapid diagnostic tests have
been placed on the market, as outlined below.
Truenat MTB (Molbio Diagnostics, India) is a miniaturized chip-
based real-time PCR run on a handheld battery-operated device
that reports results in less than an hour. Sputum is processed using
a battery-operated sample preparation device that extracts nucleic
acids using a nanoparticle-based protocol without the need for any
additional equipment. Truenat MTB has been reported to have
sensitivity and speciﬁcity similar to Xpert MTB/RIF.35,36
The EasyNAT Diagnostic Kit for Mycobacterium tuberculosis
Complex (Ustar Biotechnologies, China), is an isothermal ampliﬁ-
cation kit with a 60-min ampliﬁcation reaction step at 63 8C and
30-min visual detection using a lateral ﬂow device.37When used to
test thinned and concentrated sputum, the reported sensitivity
compared with culture on Lowenstein–Jensen were 84.1% (95% CI
79.5–88.6%) and 97.8% (95% CI 97.1–98.5%), respectively, and the
sensitivity in smear-negative cases was 59.8% (95% CI 49.8–
69.8%).38 A sample extraction kit is sold separately, but was not
used in the study.
The VereMTB assay (Veredus Laboratories, Singapore) has been
released for research use. Used with the VerePLEX Lab-on-Chip
platform it combines PCR and microarray technology to detect
M. tuberculosis, Mycobacterium avium, Mycobacterium intracellulare,
Mycobacterium simiae/kansasii/scrofulaceum, Mycobacterium
abscessus/chelonae, Mycobacterium xenopi, and Mycobacterium
fortuitum.39 It also detects resistance to rifampicin and isoniazid.
The time to result is reported as less than 3 h, but sample
extraction is not included.
Evidence from initial studies on these new tests is promising,
but further data are needed before their potential to assist TB
control can be judged. Independent studies are required in settings
representative of the intended use of the device.agnosis of tuberculosis
arget Time
(min)
Stage of
product
development
Test developers
S6110 <90 Released
to market
Ustar Biotechnologies
Ltd, China
poB <90a CE mark and
US FDA approval,
WHO endorsement
Cepheid Inc., USA
In development Ionian Technologies, Inc.,
USA/Alere, USA
S6110 and
S1081
<20 Proof of concept
study published
TwistDx, UK/Alere, USA
ibonucleoside
iphosphate
eductase gene
<60 Released to market
CE mark
Molbio Diagnostics
Pvt. Ltd, India
S6110
6S RNA
<180 Released for
research use
Veredus Laboratories,
Singapore
EP13E12
poB
60 Field trials Epistem Ltd, UK
 European Economic Area; US FDA, US Food and Drug Administration; WHO, World
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Microscopy remains the workhorse of the diagnostic laborato-
ry. It is a cheap and rapid test of reduced sensitivity compared to
culture or NAAT, and can be used for diagnosis or to monitor
treatment. It is a subjective test, reliant on the aptitude of the
operator. Replacement of the Ziehl–Neelsen stain with ﬂuorescent
alternatives and the introduction of LED microscopes has reduced
the burden on microscopists, but it remains a labour-intensive
activity.
To increase throughput without compromising accuracy, an
automated system has been developed. TBDx (Signature Mapping
Medical Sciences, USA) incorporates robotic loading of stained
slides with automated high-resolution digital image analysis to
provide a result in minutes. The system has a 200-slide capacity,
freeing technical resources and eliminating operator fatigue. Early
studies suggested improved sensitivity over the human eye, but
reduced speciﬁcity, and manual review of positive slides was
necessary.40 The application of a stepwise classiﬁcation system for
identifying objects has reduced the false-positive rate while
maintaining high sensitivity, and suggests an accuracy of 90% can
be attained.41 Performance studies are underway in Nigeria and
South Africa, with further studies planned for Asia.
A second innovation to assist the microscopist is CellScope, a
portable digital ﬂuorescence microscope that provides enlarged
digitalized images for review.42
2.4. Next-generation blood tests
Commercial tests for antibody in sera have proved disappoint-
ing, with poor sensitivity and speciﬁcity.43,44 The lack of a
distinctive antibody response and inability to differentiate latent
infection from active disease, compromises current immunoassay
technology to such an extent that in 2010 the WHO issued a
negative endorsement, urging practitioners not to use serological
tests.45 Given the multifaceted and unpredictable nature of the
infection and complexities of the immune response, the absence of
dominant host biomarkers is not surprising. Proteomic studies
have identiﬁed a large number of potential markers in the serum of
TB patients.46–48 Similarly, attempts to map host RNA transcrip-
tional signatures to detect and differentiate active disease have
revealed a complex picture.49,50
Proteomic analysis and measurement of unstable RNA tran-
scripts at the point of care is not feasible in TB endemic countries
due to technical and cost constraints. However, robust technolo-
gies for detecting proteins are available. Proof of concept for
diagnosis and accurate differentiation of disease from latent
infection has been obtained using soluble cluster of differentiation
(‘sCD’) biomarkers.51 This proprietary technology can be imple-
mented using traditional immunoassay platforms to test periph-
eral blood, which raises the possibility of developing a test for use
at the point of care.
It has been suggested that measuring local markers of the
immune response in samples taken from the site of disease may
prove more effective at detecting active disease than testing
peripheral blood. Promising results have been obtained testing
bronchial lavage with improved sensitivity for detecting pulmo-
nary disease, although some reduction in speciﬁcity was ob-
served.52,53 However, sample collection may prove problematic in
some settings.
2.5. Extrapulmonary TB
Diagnostic tools for patients with extrapulmonary disease are
limited, and frequently the only assays available are those
developed for testing sputum. The sensitivities of these testswhen applied to samples such as blood, urine, and tissue is often low
due to the paucity of bacteria in the samples, and assays may be
affected by interference or inhibition from the sample matrix. Some
patients with severe immunosuppression secrete TB antigens in
their urine. The Alere Determine TB LAM Ag tests urine for
lipoarabinomannan (LAM), a cell wall component of mycobacteria.
The assay is a ‘rule in’ test, as a negative result does not exclude the
possibility of TB. The test was found cost-effective in Sub-Saharan
Africa when used for patients with CD4 counts per mm3 of less than
100.54,55 The lateral ﬂow devices are easy to perform, rapid (less than
30 min), and may be used at the point at which care is provided for
TB or HIV. However the test is susceptible to false-positive results
from contamination with dust or faeces, and care should be taken
during sample collection.56 The test lacks accuracy if used for
patients with CD4 counts per mm3 over 200 or children.57,58
Testing for immune markers may offer a means of diagnosis if
undertaken at the site of disease59 and promising results have been
obtained for pleural TB.60–62 Assessing interferon gamma (IFN-g)
in pleural, pericardial, ascitic, and cerebrospinal ﬂuid has also
shown promise, and in a study undertaken in South Africa the
approach was found signiﬁcantly more sensitive than Xpert MTB/
RIF for pleural TB.63 The Intergam Rapid Immuno Suspension
Array, IRISA-TB (Antrum Biotech Ltd, South Africa) takes less than
2 h and is based on a multi-well plate ELISA format.
2.6. Drug resistance
Patients with MDR-TB (resistance to at least isoniazid and
rifampicin) who are prescribed ﬁrst-line drug therapy may fail
treatment and remain infectious, and are at high risk of developing
further resistance. The early detection of MDR-TB is therefore
important for both individual and public health. Resistance to
additional ﬁrst-line drugs further compromises treatment suc-
cess.64–66 Resistance to ﬂuoroquinolones and aminoglycosides
used to treat MDR-TB results in extensively drug-resistant TB
(XDR-TB).5 Drugs used in the treatment of MDR-TB and XDR-TB are
expensive, of higher toxicity, and outcomes are poor.4,67,68 Adverse
reactions are common and may be severe and irreversible.68,69
Poor tolerance leads to reduced compliance, which can result in the
ampliﬁcation of resistance.70 Knowledge of the full drug suscepti-
bility proﬁle would enable tailored treatment to improve efﬁcacy
and reduce exposure to ineffective toxic drugs.66
The genetic basis of resistance to rifampicin is well understood,
and sensitive molecular tests have been developed. Rifampicin
resistance has the additional advantage of being a good proxy for
MDR-TB. The genetic basis of resistance to other anti-TB drugs is
less well deﬁned and further work is needed to determine the
clinical impact of putative drug resistance mutations.22 Whole
genome sequencing provides the most efﬁcient means of obtaining
a complete resistance proﬁle of the bacteria,71,72 but the cost and
infrastructure required preclude its use at the point of care in TB
endemic countries.
Rapid laboratory-based tests for individual or selected drugs
have been developed, with priority given to the drugs involved in
MDR-TB and XDR-TB.73 These include the line probe assays where,
following PCR using labelled primers, hybridization to a panel of
immobilized oligonucleotide probes indicates the presence or
absence of mutations.74 The ﬁrst test to be used at the point of care
was the Xpert MTB/RIF (Cepheid), a combined diagnostic and drug
resistance test.20 The company is reported to be developing an
additional test for XDR-TB. A new product reported to be close to
the market is the Epistem Genedrive system, which in addition to
diagnosing TB detects resistance to rifampicin.75 Sample extraction
is undertaken using a novel paper-based digestion, followed by
PCR and detection with labelled probes. The VereMTB test
(Veredus Laboratories, Singapore) uses chip-based technology to
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detecting M. tuberculosis and nine other mycobacteria.39 The test
has been released for research use and is undergoing evaluation.
Both of these tests are new to the market; clinical performance
data are not yet available, and their cost and infrastructure
requirements are not known.
2.7. Barriers to the market
The case for new diagnostic tests for TB has been well made and
is supported by the STOP TB Partnership and WHO.76 However,
investment remains low and the estimated global total of USD
42.4 million spent on diagnostics research during 2012 was less
than a third that spent on basic research and one ﬁfth that spent on
developing new drugs, representing just 13% of the annual spend
called for by the STOP TB Partnership.77 Financial return on
investment to create and manufacture tests for the control of TB is
constrained by the drive to provide technology that is affordable in
TB endemic countries. The lack of market incentives creates a
social responsibility to encourage and facilitate the entry of
beneﬁcial new products into the market. Endorsement by the WHO
has encouraged the adoption of new technologies, but market
acceptance of individual products is dependent on regulatory
approval, a costly and lengthy process that requires studies to
determine clinical performance at the site of intended use.78
The arrival of new products on the market means that health
providers will soon have a choice of technologies and products
for diagnosing TB. A welcome effect of competition may be
moderation of prices, as seen in malaria and HIV where multiple
tests are already available. Technology assessment programs
will be required during which the beneﬁts and potential impact
of diagnostic tools and strategies are compared. Programs for
global rollout of a single TB diagnostic may be consigned to
history, to be replaced by procurement decisions based on local
need. It is imperative that continued research and funding
efforts are targeted towards the development of diagnostic
modalities that translate to improved patient outcomes and
reduced transmission.
3. Conclusions
Improved tools for detecting TB are urgently needed. New tests
have been developed for use in laboratories and clinics, but as yet
little is available to assist early case ﬁnding in the community. The
introduction of an easy to use molecular test that also detects
resistance to rifampicin is a welcome step forward, but its high
cost limits accessibility and increases dependency on donor
support. The Xpert MTB/RIF test continues to be evaluated;
studies to date suggest that although the test is more sensitive
than smear microscopy for diagnosis, it has limited impact when
used in settings where presumptive treatment is practised.
Several alternative products have been developed and other
technologies are being explored, including some innovative new
approaches to assist the diagnosis of extrapulmonary disease.
Sustained investment will be needed to ensure that these new
tests reach the market. Studies to assess the effectiveness of new
tests are needed to ensure appropriate placement within the
health systems of TB endemic countries and to maximize the
impact of the new technology on efforts to control and eradicate
the disease.
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